DETECTION OF MUTATIONS IN RPOB GENE RESPONSIBLE FOR RIFAMPICIN-RESISTANCE AMONG CLINICAL ISOLATES OF M. TUBERCULOSIS FROM DIFFERENT REGIONS OF KAZAKHSTAN
Spectrum of mutations in rpoB gene that cause resistance to one of the main antituberculosis drugs – rifampicin in clinical isolates of M. tuberculosis distributed in 3 regions (Almaty, Kostanay, Kyzylorda) of Kazakhstan was estimated in this study. High frequency of mutation at codon Ser531 of rpoB gene (79,2%) responsible for drug resistance to rifampicin was determined among M. tuberculosis population circulating in the mentioned regions.
А.Zh. Аkhmetova1, S.Е. Rakhimova1, V.L. Bismilda2, М.А. Darisheva3, A.R. Akilzhanova1
1Center for Life Sciences, Nazarbayev University, Astana
2 National Center for Tuberculosis Problems, Almaty
3 Global Health Research Center of Central Asia, Almaty
1. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009, 2009, p.303.
2. Shean K.P., Willcox P.A., Siwendu S.N., Laserson K.F., Gross L., Kammerer S., Wells C.D., Holtz T.H. Treat-ment outcome and follow-up of multidrug-resistant tubercu-losis patients, West Coast/Winelands, South Africa, 1992–2002. INT J TUBERC LUNG DIS, 2008, 12(10):1182–1189.
3. Anti-tuberculosis drug resistance in the world Fourth Global Report: The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 2002-2007. World Health Organization 2008.
4. Mohamed Abdel Aziz, Abigail Wright, Adalbert Laszlo, Aimé De Muynck, Françoise Portaels, Armand Van Deun, Charles Wells, Paul Nunn, Leopold Blanc, Mario Raviglione Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis Lancet, 2006, 368: 2142–54.
5. Статистический сборник по туберкулезу по Рес-публике Казахстан: Национальный центр проблем ту-беркулеза МЗ РК, - 2009, - 68 c.
6. Jindani A., Aber V.R., Edwards E.A., Mitchison D.A. The early bactericidal activity of drugs in patients with pul-monary tuberculosis. Am. Rev. Respir. Dis., 1980, 121: 939–949.
7. Dickinson J.M., Mitchison D.A. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis, Am. Rev. Respir. Dis., 1981, 123:367–371.
8. Gale E.F., Cundliffe E., Reynolds P.E., Richmond M.H., and Waring M.J. 1981. The molecular basis of antibiotic action. John Wiley & Sons, Inc., New York.
9. Telenti A., Imboden P., Marchesi F., Matter L., Schopfer K., Bodmer T., Lowrie D., Colston M.J. and Cole S. Detection of rifampicin-resistance mutations in Mycobac-terium tuberculosis, Lancet, 1993, 341 (8846): 647-651.
Көрген адамдардың саны: 354
Мақалалар санаты:
Мақалалар
Библиографиялық сілтемелер
А.Ж. Ахметова1, С.Е. Рахимова1, В.Л. Бисмилда2, М.А. Даришева3, А.Р. Акилжанова1 ОПРЕДЕЛЕНИЕ МУТАЦИЙ В RPOB ГЕНЕ, ОБУСЛАВЛИВАЮЩИХ УСТОЙЧИВОСТЬ К РИФАМПИЦИНУ СРЕДИ КЛИНИЧЕСКИХ ИЗОЛЯТОВ M. TUBERCULOSIS ИЗ РАЗЛИЧНЫХ ОБЛАСТЕЙ КАЗАХСТАНА //Наука и Здравоохранение 2014.№ 4. С. 26-27 А.Zh. Аkhmetova1, S.Е. Rakhimova1, V.L. Bismilda2, М.А. Darisheva3, A.R. Akilzhanova1 DETECTION OF MUTATIONS IN RPOB GENE RESPONSIBLE FOR RIFAMPICIN-RESISTANCE AMONG CLINICAL ISOLATES OF M. TUBERCULOSIS FROM DIFFERENT REGIONS OF KAZAKHSTAN // Nauka i Zdravookhranenie. 2014.№ 4. С. 26-27 А.Ж. Ахметова1, С.Е. Рахимова1, В.Л. Бісмілда2, М.А. Даришева3, А.Р. Ақылжанова1 ҚАЗАҚСТАННЫҢ ӘР ТҮРЛІ ОБЛЫСТАРЫНДА ТАРАЛҒАН M. TUBERCULOSIS ИЗОЛЯТТАРЫНЫҢ РИФАМПИЦИНГЕ ТӨЗІМДІЛІГІН АНЫҚТАЙТЫН RPOB ГЕНІНДЕ МУТАЦИЯЛАРДЫ АНЫҚТАУ // Ғылым және Денсаулық сақтау 2014.№ 4. С. 26-27Ұқсас жариялымдар:
INDICATORS OF DAILY MONITORING OF THE BLOOD PRESSURE IN CHILDREN WITH ARTERIAL HYPERTENSION BORN FROM IRRADIATED PARENTS
ANALYSIS OF TRENDS IN THE INCIDENCE OF HOSPITALIZED ACUTE MYOCARDIAL INFARCTION IN SEMEY REGION
RISK FACTORS FOR CERVICAL CANCER IN SEMEY REGION
DETECTION OF MUTATIONS IN RPOB GENE RESPONSIBLE FOR RIFAMPICIN-RESISTANCE AMONG CLINICAL ISOLATES OF M. TUBERCULOSIS FROM DIFFERENT REGIONS OF KAZAKHSTAN
EFFICIENCY OF APPLICATION OF POLARIZED LIGHT AND PREPARATION OF NITROGEN OXIDE DONOR FOR THE PURPOSE OF CORRECTION ENDOTHELIAL DYSFUNCTION AT PATIENTS WITH FIXED ORTHODONTIC TECHNICS